PDF is committed to using your funds efficiently to support our mission. To see how funds are spent, browse our financial information.
Neupro Patch Re-launches in the US
- Jul 17 2012
UCB Inc. announced Monday that Neupro®, a once-daily skin patch used to treat the symptoms of Parkinson’s disease and restless legs syndrome, is now available in pharmacies in the United States (US). The patch provides continuous delivery of the dopamine agonist rotigotine for 24 hours.
Neupro was reapproved by the US Food and Drug Administration (FDA) in April 2012 to treat the signs and symptoms of early and advanced stage Parkinson's disease.
It was first approved as a treatment for early stage Parkinson’s in 2007, but was removed from the market in 2008 after a manufacturing issue which caused the medication to crystallize, thereby lowering its effectiveness.
According to UCB, over 100,000 people have been treated with Neupro worldwide. It is available in four different dosage strengths to treat Parkinson’s disease symptoms. Side effects may include nausea, vomiting, somnolence, application site reactions, dizziness, anorexia, hyperhidrosis, insomnia, peripheral edema and dyskinesia.
Do you have additional questions about medications available to treat Parkinson’s disease? Review PDF’s fact sheet with your doctor so you know your options.
Download Medication Fact Sheet
Source Date: Jul 17 2012